Choose the experimental features you want to try

This document is an excerpt from the EUR-Lex website

Document 62021TA0543

    Case T-543/21: Judgment of the General Court of 13 July 2022 — Purasac v EUIPO — Prollenium Medical Technologies (Rejeunesse) (EU trade mark — Opposition proceedings — Application for the EU figurative mark Rejeunesse — Earlier EU word mark REVANESSE — Relative ground for refusal — Likelihood of confusion — Article 8(1)(b) of Regulation (EU) 2017/1001)

    OJ C 359, 19.9.2022, p. 68–69 (BG, ES, CS, DA, DE, ET, EL, EN, FR, GA, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)

    19.9.2022   

    EN

    Official Journal of the European Union

    C 359/68


    Judgment of the General Court of 13 July 2022 — Purasac v EUIPO — Prollenium Medical Technologies (Rejeunesse)

    (Case T-543/21) (1)

    (EU trade mark - Opposition proceedings - Application for the EU figurative mark Rejeunesse - Earlier EU word mark REVANESSE - Relative ground for refusal - Likelihood of confusion - Article 8(1)(b) of Regulation (EU) 2017/1001)

    (2022/C 359/83)

    Language of the case: English

    Parties

    Applicant: Purasac Co. Ltd (Anyang-si, South Korea) (represented by: P. Lee, lawyer)

    Defendant: European Union Intellectual Property Office (represented by: E. Sliwinska and J. Crespo Carrillo, acting as Agents)

    Other party to the proceedings before the Board of Appeal of EUIPO, intervener before the General Court: Prollenium Medical Technologies, Inc. (Aurora, Ontario, Canada) (represented by: R. Lyxell, lawyer)

    Re:

    By its action brought under Article 263 TFEU, the applicant seeks annulment of the decision of the Fourth Board of Appeal of the European Union Intellectual Property Office (EUIPO) of 2 July 2021 (Case R 146/2021-4).

    Operative part of the judgment

    The Court:

    1.

    Dismisses the action;

    2.

    Orders Purasac Co. Ltd to pay the costs.


    (1)  OJ C 422, 18.10.2021.


    Top